333 related articles for article (PubMed ID: 24612412)
1. A cross sectional study of p504s, CD133, and Twist expression in the esophageal metaplasia dysplasia adenocarcinoma sequence.
Ahmad J; Arthur K; Maxwell P; Kennedy A; Johnston BT; Murray L; McManus DT
Dis Esophagus; 2015 Apr; 28(3):276-82. PubMed ID: 24612412
[TBL] [Abstract][Full Text] [Related]
2. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
3. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
Goodarzi M; Correa AM; Ajani JA; Swisher SG; Hofstetter WL; Guha S; Deavers MT; Rashid A; Maru DM
Mod Pathol; 2009 Dec; 22(12):1612-21. PubMed ID: 19734842
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical assessment of Survivin and Bcl3 expression as potential biomarkers for NF-κB activation in the Barrett metaplasia-dysplasia-adenocarcinoma sequence.
Puccio I; Khan S; Butt A; Graham D; Sehgal V; Patel D; Novelli M; Lovat LB; Rodriguez-Justo M; Hamoudi RA
Int J Exp Pathol; 2018 Feb; 99(1):10-14. PubMed ID: 29473241
[TBL] [Abstract][Full Text] [Related]
5. Metallothionein in human oesophagus, Barrett's epithelium and adenocarcinoma.
Coyle P; Mathew G; Game PA; Myers JC; Philcox JC; Rofe AM; Jamieson GG
Br J Cancer; 2002 Aug; 87(5):533-6. PubMed ID: 12189552
[TBL] [Abstract][Full Text] [Related]
6. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation.
Chinyama CN; Marshall RE; Owen WJ; Mason RC; Kothari D; Wilkinson ML; Sanderson JD
Histopathology; 1999 Dec; 35(6):517-24. PubMed ID: 10583575
[TBL] [Abstract][Full Text] [Related]
7. Surveillance in Barrett's esophagus: an audit of practice.
Ajumobi A; Bahjri K; Jackson C; Griffin R
Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
[TBL] [Abstract][Full Text] [Related]
8. Endoscopic Raman spectroscopy enables objective diagnosis of dysplasia in Barrett's esophagus.
Almond LM; Hutchings J; Lloyd G; Barr H; Shepherd N; Day J; Stevens O; Sanders S; Wadley M; Stone N; Kendall C
Gastrointest Endosc; 2014 Jan; 79(1):37-45. PubMed ID: 23886354
[TBL] [Abstract][Full Text] [Related]
9. Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus.
Makita K; Kitazawa R; Semba S; Fujiishi K; Nakagawa M; Haraguchi R; Kitazawa S
World J Gastroenterol; 2013 Jan; 19(4):536-41. PubMed ID: 23382633
[TBL] [Abstract][Full Text] [Related]
10. Trefoil Factor Expression in a Human Model of the Early Stages of Barrett's Esophagus.
Dunn LJ; Jankowski JA; Griffin SM
Dig Dis Sci; 2015 May; 60(5):1187-94. PubMed ID: 25424203
[TBL] [Abstract][Full Text] [Related]
11. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
12. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
13. Increasing diagnostic accuracy to grade dysplasia in Barrett's esophagus using an immunohistochemical panel for CDX2, p120ctn, c-Myc and Jagged1.
Karamchandani DM; Lehman HL; Ohanessian SE; Massé J; Welsh PA; Odze RD; Goldblum JR; Berg AS; Stairs DB
Diagn Pathol; 2016 Feb; 11():23. PubMed ID: 26926447
[TBL] [Abstract][Full Text] [Related]
14. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
Whitson MJ; Falk GW
Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
[TBL] [Abstract][Full Text] [Related]
16. Does Risk of Progression from Barrett's Esophagus to Esophageal Adenocarcinoma Change Based on the Number of Non-dysplastic Endoscopies?
Kunzmann AT; Coleman HG; Johnston BT; Turkington RC; McManus D; Anderson LA; Thrift AP
Dig Dis Sci; 2021 Jun; 66(6):1965-1973. PubMed ID: 32734400
[TBL] [Abstract][Full Text] [Related]
17. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study.
Cameron AJ; Carpenter HA
Am J Gastroenterol; 1997 Apr; 92(4):586-91. PubMed ID: 9128304
[TBL] [Abstract][Full Text] [Related]
18. Time gated fluorescence spectroscopy in Barrett's oesophagus.
Ortner MA; Ebert B; Hein E; Zumbusch K; Nolte D; Sukowski U; Weber-Eibel J; Fleige B; Dietel M; Stolte M; Oberhuber G; Porschen R; Klump B; Hörtnagl H; Lochs H; Rinneberg H
Gut; 2003 Jan; 52(1):28-33. PubMed ID: 12477755
[TBL] [Abstract][Full Text] [Related]
19. Methylene blue staining of dysplastic and nondysplastic Barrett's esophagus: an in vivo and ex vivo study.
Canto MI; Setrakian S; Willis JE; Chak A; Petras RE; Sivak MV
Endoscopy; 2001 May; 33(5):391-400. PubMed ID: 11396755
[TBL] [Abstract][Full Text] [Related]
20. Dysplasia in Barrett's esophagus. A clinicopathologic study of six patients.
Lee RG
Am J Surg Pathol; 1985 Dec; 9(12):845-52. PubMed ID: 2416226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
